Isolation and Sequencing of Deer and Sheep Insulin-like Growth Factors-I and -II

Moore, L. G.; Jones, D. R.; Lymburn, Moira A.; Hodgkinson, S. C.; Davis, Stephen R.; Suttie, J. M.; Sadighi, M; Carne, Alan

doi:10.1006/gcen.1993.1166

Cited by 16 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…L6 myoblast proliferation in these studies was doseresponsive to IGF-I up to 48 h, confirming earlier work (Ballard et al 1986, Ewton et al 1987, Moore et al 1993. Although myoblasts proliferated in response to IGF-I, they did so for only 30 to 36 h, regardless of concentration.…”

Section: Discussionsupporting

confidence: 89%

Insulin-like growth factor-I protects myoblasts from apoptosis but requires other factors to stimulate proliferation

Napier

Thomas²,

Sharma³

et al. 1999

Journal of Endocrinology

View full text Add to dashboard Cite

Insulin-like growth factor-I (IGF-I) has been shown to stimulate myoblast proliferation for a limited time after which serum is required to reactivate IGF-I-stimulated myoblast proliferation. The aim of these studies was to determine whether IGF-I can stimulate myoblast proliferation and/or inhibit apoptosis alone or whether co-factors are necessary. This was achieved by investigating the proliferative response of L6 myoblasts to IGF-I and horse serum (HS) and by examining the status of cells in terms of cell number, substrate adherence, cell viability and DNA laddering following incubation with IGF-I and HS.

show abstract

Section: Discussionsupporting

confidence: 89%

Insulin-like growth factor-I protects myoblasts from apoptosis but requires other factors to stimulate proliferation

Napier

Thomas²,

Sharma³

et al. 1999

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Both preparations of IGF-I were found to be homogeneous; however, IGF-II was purified to homogeneity on one occasion only. These yields compare favourably with those reported for many other purifications from serum , 1989a,b, Dawe et al 1988, Moore et al 1993.…”

Section: Discussionsupporting

confidence: 87%

“…In previously reported purifications of IGFs from other sera, IGF-I and IGF-II were not separated by a similar reversephase HPLC step , 1989a,b, Dawe et al 1988, Moore et al 1993. Instead, an additional cation-exchange chromatography step has been required to separate the two IGFs.…”

Section: Discussionmentioning

confidence: 99%

Purification, amino acid sequence and characterisation of kangaroo IGF-I

Yandell

Francis²,

Wheldrake³

et al. 1998

Journal of Endocrinology

View full text Add to dashboard Cite

Insulin-like growth factor-I (IGF-I) and IGF-II have been purified to homogeneity from kangaroo (Macropus fuliginosus) serum, thus this represents the first report of the purification, sequencing and characterisation of marsupial IGFs. N-Terminal protein sequencing reveals that there are six amino acid differences between kangaroo and human IGF-I. Kangaroo IGF-II has been partially sequenced and no differences were found between human and kangaroo IGF-II in the 53 residues identified. Thus the IGFs appear to be remarkably structurally conserved during mammalian radiation. In addition, in vitro characterisation of kangaroo IGF-I demonstrated that the functional properties of human, kangaroo and chicken IGF-I are very similar. In an assay measuring the ability of the proteins to stimulate protein synthesis in rat L6 myoblasts, all IGF-I proteins were found to be equally potent. The ability of all three proteins to compete for binding with radiolabelled human IGF-I to type-1 IGF receptors in L6 myoblasts and in Sminthopsis crassicaudata transformed lung fibroblasts, a marsupial cell line, was comparable. Furthermore, kangaroo and human IGF-I react equally in a human IGF-I RIA using a human reference standard, radiolabelled human IGF-I and a polyclonal antibody raised against recombinant human IGF-I. This study indicates that not only is the primary structure of eutherian and metatherian IGF-I conserved, but also the proteins appear to be functionally similar.

show abstract

“…IGF-1 was purified to homogeneity from ovine plasma (Moore et al, 1990) and showed equal potency and cross-reactivity to recombinant IGF in all systems so far investigated (Hodgkinson et al, 1989;Spencer et al, 1991 b). Anti-somatostatin serum was raised in sheep to a somatostatin-human serum globulin conjugate (Spencer et al, 1983b) As in earlier studies (Spencer et al, 1989b(Spencer et al, , 1991a, there was no significant change in GH levels following either saline or normal serum given in a similar volume into a lateral cerebral ventricle (fig 3), but a marked variation in GH secretion was seen in individual control animals.…”

Section: Methodsmentioning

confidence: 99%

Decreased circulating growth hormone levels following centrally administered insulin-like growth factor-1 is not mediated by somatostatin in the pig fetus

Spencer¹,

Macdonald²,

Carlyle³

et al. 1991

Reprod. Nutr. Dev.

View full text Add to dashboard Cite

Summary ― Twenty-six pig fetuses (at 94 days gestational age) were fitted with carotid artery catheters. Eight fetuses were given 1 500 ng of IGF-1 (in 100 pl) directly into a lateral cerebral ventricle; 7 further fetuses received the IGF-1 together with 150 pl of a potent specific anti-somatostatin serum into a ventricle, 5 other fetuses received the anti-somatostatin serum alone while 6 controls received normal sheep serum. Administration of IGF-1 caused a rapid decrease in circulating growth hormone (pGH) levels but there was no significant change in plasma levels of somatostatin immediately following the IGF-1 administration, suggesting that the decrease in pGH was not mediated by somatostatin secretion. Further evidence that somatostatin was not involved in this effect was provided by the lack of effect of concurrent antisomatostatin serum on the IGF-1-induced decrease in pGH. Thus the high circulating levels of GH in the fetus may result from a lack of feedback of IGF-1, but not through the somatostatin-pituitary axis.pig / fetus / IGF-1 / somatostatin / growth hormone Résumé ― La diminution des niveaux d'hormone de croissance circulante après administration centrale d'IGF-1 (insulin-like growth factor 1 ) n'est pas régulée par la somatostatine chez les foetus de porc. Vingt-six foetus de porc (à 94 j de la gestation) ont été équipés de catheters intracardotidiens. Huit d'entre eux ont reçu 1 500 ng d'IGF-1 pur (dans 100 J 11), directement dans un ventricule cérébral latéral; 7 autres ont reçu / 7 GF-? mélangé à 150 pl d'un puissant antiserum spéci-fique de la somatostatine dans un ventricule, 5 autres encore ont reçu l'antisérum seul tandis que 6 témoins recevaient serum normale. L'administration de l'IGF-1 a provoqué une chute rapide de la concentration de pGH circulante sans que simultanément soit noté un changement significatif du niveau plasmatiques de somatostatine ce qui suggère que la chute de pGH n'était pas due à une sé-crétion de somatostatine. Une autre preuve que la somatostatine n'intervient pas dans ce processus fut l'absence d'effet de l'antisérum anti-somatostatine sur la chute de pGH induite par l'IGF-1. Ainsi les niveaux élevés de GH circulante chez les foetus pourraient provenir non pas d'une absence de retrocontrôle par IGF-1 mais d'une immaturité de l'axe somatostatine-hypophyse foetale.

show abstract

Isolation and Sequencing of Deer and Sheep Insulin-like Growth Factors-I and -II

Cited by 16 publications

References 0 publications

Insulin-like growth factor-I protects myoblasts from apoptosis but requires other factors to stimulate proliferation

Insulin-like growth factor-I protects myoblasts from apoptosis but requires other factors to stimulate proliferation

Purification, amino acid sequence and characterisation of kangaroo IGF-I

Decreased circulating growth hormone levels following centrally administered insulin-like growth factor-1 is not mediated by somatostatin in the pig fetus

Contact Info

Product

Resources

About